<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02630186</url>
  </required_header>
  <id_info>
    <org_study_id>CO-1686-032</org_study_id>
    <nct_id>NCT02630186</nct_id>
  </id_info>
  <brief_title>A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC</brief_title>
  <official_title>A Phase 1b/2 Study of the Safety and Efficacy of Rociletinib (CO-1686) Administered in Combination With MPDL3280A in Patients With Activating EGFR Mutation-positive (EGFRm) Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clovis Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Clovis Oncology, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical research study is being carried out in two parts, Phase 1 and Phase 2. The
      primary purpose of the Phase 1 portion of the study is to observe the safety of the
      combination of rociletinib and MPDL3280A in EGFR-mutant NSCLC patients.

      The primary purpose of the Phase 2 portion of the study is to evaluate the safety and
      anti-tumor effects of the combination of rociletinib and MPDL3280A, at the best doses for the
      combination determined in Phase 1, in patients with EGFR-mutant NSCLC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1b/2, open-label, non-randomized, multicenter study evaluating the safety and
      efficacy of rociletinib administered in combination with MPDL3280A.

      Phase 1: This will be the dose finding phase of the study. Patients will be enrolled to
      available Dosing Cohort. Patients who have progressed after prior first- or second-generation
      EGFR TKI, regardless of T790M mutation status, will be enrolled.

      Phase 2: Patients will be enrolled into 2 groups. Group A will enroll eligible first-line
      patients who are EGFR TKI treatment-na誰ve and chemotherapy-na誰ve. Group B will enroll
      eligible patients who have progressed after prior first- or second-generation EGFR TKI,
      regardless of T790M mutation status.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study terminated before Phase 1 was completed. This study was reprioritized within the
    rociletinib development program.
  </why_stopped>
  <start_date type="Actual">February 24, 2016</start_date>
  <completion_date type="Actual">September 5, 2017</completion_date>
  <primary_completion_date type="Actual">September 5, 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Treatment-emergent Adverse Events, as Assessed by NCI CTCAE v4.03</measure>
    <time_frame>Continuously, up to approximately 18.5 months</time_frame>
    <description>The safety analyses will be performed using the safety population. Safety data analysis will be conducted on all patients receiving at least one dose of rociletinib or MPDL3280A.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Concentration (Cmax) of Rociletinib and Its Metabolites</measure>
    <time_frame>Treatment Day 1 and Day 15</time_frame>
    <description>Blood sampling for PK analyses of both rociletinib and MPDL3280A will be conducted in all patients treated with rociletinib and MPDL3280A. Cmax will be estimated for rociletinib, using non-compartmental models. Comparisons across dose levels will be made to assess proportionality.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Concentration (Tmax) for Rociletinib and Rociletinib Metabolites</measure>
    <time_frame>Treatment Day 1 and Day 15</time_frame>
    <description>Blood sampling for PK analyses of both rociletinib and MPDL3280A will be conducted in all patients treated with rociletinib and MPDL3280A. Tmax will be estimated for rociletinib, using non-compartmental models. Comparisons across dose levels will be made to assess proportionality.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimum Concentration (Cmin) of Rociletinib and Metabolites</measure>
    <time_frame>Approximately every 6 weeks up to 24 months</time_frame>
    <description>Blood sampling for PK analyses of both rociletinib and MPDL3280A will be conducted in all patients treated with rociletinib and MPDL3280A. Cmin will be estimated for rociletinib, using non-compartmental models. Comparisons across dose levels will be made to assess proportionality.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve (AUC) of Rociletinib and Rociletinib Metabolites</measure>
    <time_frame>Treatment Day 1 and Day 8</time_frame>
    <description>Blood sampling for PK analyses of both rociletinib and MPDL3280A will be conducted in all patients treated with rociletinib and MPDL3280A. AUC0 24 will be estimated for rociletinib, using non-compartmental models. Comparisons across dose levels will be made to assess proportionality.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Concentration (Cmax) of MPDL3280A</measure>
    <time_frame>Cycle 1 Day 1</time_frame>
    <description>Blood sampling for PK analyses of both rociletinib and MPDL3280A will be conducted in all patients treated with rociletinib and MPDL3280A. Cmax, for MPDL3280A will be assessed using non-compartmental models. Comparisons across dose levels will be made to assess proportionality.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimum Concentration (Cmin) of MPDL3280A</measure>
    <time_frame>Approximately every 6 weeks up to 24 months</time_frame>
    <description>Blood sampling for PK analyses of both rociletinib and MPDL3280A will be conducted in all patients treated with rociletinib and MPDL3280A. Cmin for MPDL3280A will be assessed using non-compartmental models. Comparisons across dose levels will be made to assess proportionality.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate Per RECIST v1.1 in Phase 2</measure>
    <time_frame>Approximately every 6-9 weeks</time_frame>
    <description>To determine the efficacy of the combination of rociletinib and MPDL3280A based on overall response rate per RECIST v1.1 in the following groups of patients:
Group A: Patients with EGFRm advanced or metastatic NSCLC who have not previously received an EGFR TKI or chemotherapy.
Group B: Patients with EGFRm advanced or metastatic NSCLC who have progressed on a prior EGFR TKI.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate Per Modified RECIST v1.1, Incorporating Immune-related Criteria, in Phase 2</measure>
    <time_frame>Approximately every 6-9 weeks, up to 24 months</time_frame>
    <description>Conventional response criteria may not be adequate to characterize the antitumor activity of immunotherapeutic agents like MPDL3280A, which can produce delayed responses that may be preceded by initial apparent radiological progression, including the appearance of new lesions. Therefore, modified response criteria have been developed that account for the possible appearance of new lesions and allow radiological progression to be confirmed at a subsequent assessment. In this protocol, patients will be permitted to continue study treatment even after modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria for progressive disease are met if the benefit-risk ratio is judged to be favorable.
These modified criteria are derived from RECIST version 1.1 (v1.1) conventions and immune related response criteria (irRC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response Per RECIST v1.1 and Modified RECIST v1.1, Incorporating Immune-related Criteria, in Phase 2</measure>
    <time_frame>Approximately every 6-9 weeks, up to 24 months</time_frame>
    <description>Conventional response criteria may not be adequate to characterize the antitumor activity of immunotherapeutic agents like MPDL3280A, which can produce delayed responses that may be preceded by initial apparent radiological progression, including the appearance of new lesions. Therefore, modified response criteria have been developed that account for the possible appearance of new lesions and allow radiological progression to be confirmed at a subsequent assessment. In this protocol, patients will be permitted to continue study treatment even after modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria for progressive disease are met if the benefit-risk ratio is judged to be favorable.
These modified criteria are derived from RECIST version 1.1 (v1.1) conventions and immune related response criteria (irRC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival Per RECIST v1.1 and Modified RECIST v1.1, Incorporating Immune-related Criteria, in Phase 2</measure>
    <time_frame>Approximately every 6-9 weeks, up to 24 months</time_frame>
    <description>Conventional response criteria may not be adequate to characterize the antitumor activity of immunotherapeutic agents like MPDL3280A, which can produce delayed responses that may be preceded by initial apparent radiological progression, including the appearance of new lesions. Therefore, modified response criteria have been developed that account for the possible appearance of new lesions and allow radiological progression to be confirmed at a subsequent assessment. In this protocol, patients will be permitted to continue study treatment even after modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria for progressive disease are met if the benefit-risk ratio is judged to be favorable.
These modified criteria are derived from RECIST version 1.1 (v1.1) conventions and immune related response criteria (irRC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Alive at Study Termination</measure>
    <time_frame>Up to approximately 18.5 months</time_frame>
    <description>Patients who received the combination of rociletinib and MPDL3280A alive at the termination of this study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Longitudinal Changes in Blood Based Biomarkers (eg, Mutations in EGFR) in ctDNA</measure>
    <time_frame>Blood samples will be collected from each patient approximately every 3 weeks, up to 24 months</time_frame>
    <description>Tumor tissue, plasma, and blood specimens will be used for pharmacodynamic assessment of rociletinib and/or MPDL3280A activity, to evaluate the concordance of mutant EGFR detection between tissue and plasma, and to explore biomarkers that may be predictive of response or resistance to rociletinib and/or MPDL3280A. Biomarkers and changes in biomarker status will be investigated for associations with rociletinib and/or MPDL3280A exposure, safety, and clinical activity. Given the limited sample size, no formal statistical analysis is planned.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Single Arm Rociletinib and MPDL3280A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Specific doses of rociletinib, taken continuously BID, will be administered in combination with a fixed dose of MPDL3280A, given intravenously on Day 1 of each 21-day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rociletinib</intervention_name>
    <description>A novel, potent, covalent (irreversible) small molecule, tyrosine kinase inhibitor (TKI) administered orally (PO) to patients with EGFRm NSCLC.</description>
    <arm_group_label>Single Arm Rociletinib and MPDL3280A</arm_group_label>
    <other_name>CO-1686</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MPDL3280A</intervention_name>
    <description>A human IgG1 monoclonal antibody administered intravenously (IV)</description>
    <arm_group_label>Single Arm Rociletinib and MPDL3280A</arm_group_label>
    <other_name>atezolizumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ECOG performance status of 0 or 1

          -  Adequate hematological and biological function, confirmed by defined laboratory values

          -  Histologically or cytologically documented metastatic or unresectable, locally
             advanced or metastatic NSCLC, with one or more activating EGFR mutation (eg, G719X,
             exon 19 deletion, L858R, L861Q) and absence of exon 20 insertion

          -  Measurable disease as defined by RECIST v1.1

          -  Biopsy of tumor tissue for central evaluation, within 60 days prior to the first day
             of study treatment

          -  For Phase 1 and Phase 2 Group B, progression after prior 1st or 2nd generation EGFR
             TKI (eg, erlotinib, gefitinib, afatinib). Previous chemotherapy for NSCLC is allowed.

          -  For Phase 2 Group A, EGFR TKI treatment-na誰ve and chemotherapy-na誰ve

        Exclusion Criteria:

          -  Unresolved toxicities from prior therapy

          -  Symptomatic, untreated or unstable central nervous system or leptomeningeal metastases

          -  Previous treatment with rociletinib or MPDL3280A, or other 3rd generation EGFR TKI
             (eg, AZD-9291, HM61713), or PD 1 axis targeted therapy (eg, anti PD 1 or anti-PD L1)

          -  Prior treatment with CD137 agonists or other immune checkpoint blockade therapies,
             including anti-CTLA-4 therapeutic antibodies

          -  Uncontrolled pleural effusion, pericardial effusion or ascites requiring recurrent
             drainage procedures

          -  Uncontrolled hypercalcemia or symptomatic hypercalcemia requiring continued use of
             bisphosphonate therapy or denosumab (bisphosphonate use for prevention of skeletal
             events allowed)

          -  Known hypersensitivity to any component of the MPDL3280A or rociletinib formulations
             or history or hypersensitivity to chimeric humanized antibodies or fusion proteins

          -  History of autoimmune disease

          -  History of prior allogeneic hematopoietic stem cell transplantation or prior solid
             organ transplantation

          -  Treatment with systemic immunosuppressive medications within 2 weeks prior to first
             day of study treatment (inhaled corticosteroids and mineralocorticoids allowed)

          -  Live attenuated vaccine within 4 weeks prior to first day of study treatment

          -  Active tuberculosis, active hepatitis, or positive HIV status

          -  Class II to IV heart failure as defined by the New York Heart Association functional
             classification system

          -  Untreated or uncontrolled cardiovascular disease or other symptomatic cardiac
             dysfunction

          -  QTCF &gt; 450 ms, inability to measure QT interval on ECG, personal or family history of
             long QT syndrome, requirement for medications that have the potential to prolong the
             QT interval

          -  History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced
             pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening
             chest computerized tomography (CT) scan (history of radiation pneumonitis in radiation
             field may be allowed)

          -  Other malignancies within 5 years prior to enrollment, with the exception of carcinoma
             in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer,
             or ductal carcinoma in situ
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lindsey Rolfe, MD</last_name>
    <role>Study Director</role>
    <affiliation>Clovis Oncology, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California at Los Angeles</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>December 2, 2015</study_first_submitted>
  <study_first_submitted_qc>December 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2015</study_first_posted>
  <results_first_submitted>November 1, 2018</results_first_submitted>
  <results_first_submitted_qc>June 28, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 5, 2019</results_first_posted>
  <last_update_submitted>June 28, 2019</last_update_submitted>
  <last_update_submitted_qc>June 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 26, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/86/NCT02630186/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Three patients were enrolled at a single center in the United States.</recruitment_details>
      <pre_assignment_details>The Dose Finding Phase included a 7 day Run in Period of rociletinib monotherapy, at the Dosing Cohort-defined dose level, prior to the initiation of combination treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Single Arm Rociletinib and MPDL3280A in Combination</title>
          <description>Rociletinib (CO-1686), a novel, potent, covalent (irreversible) small molecule, tyrosine kinase inhibitor (TKI) administered orally (PO) to patients with EGFRm NSCLC in combination with MPDL3280A, a human IgG1 monoclonal antibody administered intravenously (IV).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Single Arm Rociletinib and MPDL3280A in Combination</title>
          <description>Rociletinib (CO-1686), a novel, potent, covalent (irreversible) small molecule, tyrosine kinase inhibitor (TKI) administered orally (PO) to patients with EGFRm NSCLC in combination with MPDL3280A, a human IgG1 monoclonal antibody administered intravenously (IV).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66" lower_limit="54" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Treatment-emergent Adverse Events, as Assessed by NCI CTCAE v4.03</title>
        <description>The safety analyses will be performed using the safety population. Safety data analysis will be conducted on all patients receiving at least one dose of rociletinib or MPDL3280A.</description>
        <time_frame>Continuously, up to approximately 18.5 months</time_frame>
        <population>All patients enrolled in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Arm Rociletinib and MPDL3280A in Combination</title>
            <description>Rociletinib (CO-1686), a novel, potent, covalent (irreversible) small molecule, tyrosine kinase inhibitor (TKI) administered orally (PO) to patients with EGFRm NSCLC in combination with MPDL3280A, a human IgG1 monoclonal antibody administered intravenously (IV).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Treatment-emergent Adverse Events, as Assessed by NCI CTCAE v4.03</title>
          <description>The safety analyses will be performed using the safety population. Safety data analysis will be conducted on all patients receiving at least one dose of rociletinib or MPDL3280A.</description>
          <population>All patients enrolled in the study.</population>
          <units>Treatment emergent adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Concentration (Cmax) of Rociletinib and Its Metabolites</title>
        <description>Blood sampling for PK analyses of both rociletinib and MPDL3280A will be conducted in all patients treated with rociletinib and MPDL3280A. Cmax will be estimated for rociletinib, using non-compartmental models. Comparisons across dose levels will be made to assess proportionality.</description>
        <time_frame>Treatment Day 1 and Day 15</time_frame>
        <population>Due to the small number of patients enrolled and small number of PK samples collected as a result of early termination of the study, these analyses were not conducted.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Arm Rociletinib and MPDL3280A in Combination</title>
            <description>Rociletinib (CO-1686), a novel, potent, covalent (irreversible) small molecule, tyrosine kinase inhibitor (TKI) administered orally (PO) to patients with EGFRm NSCLC in combination with MPDL3280A, a human IgG1 monoclonal antibody administered intravenously (IV).</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Concentration (Cmax) of Rociletinib and Its Metabolites</title>
          <description>Blood sampling for PK analyses of both rociletinib and MPDL3280A will be conducted in all patients treated with rociletinib and MPDL3280A. Cmax will be estimated for rociletinib, using non-compartmental models. Comparisons across dose levels will be made to assess proportionality.</description>
          <population>Due to the small number of patients enrolled and small number of PK samples collected as a result of early termination of the study, these analyses were not conducted.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Maximum Concentration (Tmax) for Rociletinib and Rociletinib Metabolites</title>
        <description>Blood sampling for PK analyses of both rociletinib and MPDL3280A will be conducted in all patients treated with rociletinib and MPDL3280A. Tmax will be estimated for rociletinib, using non-compartmental models. Comparisons across dose levels will be made to assess proportionality.</description>
        <time_frame>Treatment Day 1 and Day 15</time_frame>
        <population>Due to the small number of patients enrolled and small number of PK samples collected as a result of early termination of the study, these analyses were not conducted.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Arm Rociletinib and MPDL3280A in Combination</title>
            <description>Rociletinib (CO-1686), a novel, potent, covalent (irreversible) small molecule, tyrosine kinase inhibitor (TKI) administered orally (PO) to patients with EGFRm NSCLC in combination with MPDL3280A, a human IgG1 monoclonal antibody administered intravenously (IV).</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Concentration (Tmax) for Rociletinib and Rociletinib Metabolites</title>
          <description>Blood sampling for PK analyses of both rociletinib and MPDL3280A will be conducted in all patients treated with rociletinib and MPDL3280A. Tmax will be estimated for rociletinib, using non-compartmental models. Comparisons across dose levels will be made to assess proportionality.</description>
          <population>Due to the small number of patients enrolled and small number of PK samples collected as a result of early termination of the study, these analyses were not conducted.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Minimum Concentration (Cmin) of Rociletinib and Metabolites</title>
        <description>Blood sampling for PK analyses of both rociletinib and MPDL3280A will be conducted in all patients treated with rociletinib and MPDL3280A. Cmin will be estimated for rociletinib, using non-compartmental models. Comparisons across dose levels will be made to assess proportionality.</description>
        <time_frame>Approximately every 6 weeks up to 24 months</time_frame>
        <population>Due to the small number of patients enrolled and small number of PK samples collected as a result of early termination of the study, these analyses were not conducted.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Arm Rociletinib and MPDL3280A in Combination</title>
            <description>Rociletinib (CO-1686), a novel, potent, covalent (irreversible) small molecule, tyrosine kinase inhibitor (TKI) administered orally (PO) to patients with EGFRm NSCLC in combination with MPDL3280A, a human IgG1 monoclonal antibody administered intravenously (IV).</description>
          </group>
        </group_list>
        <measure>
          <title>Minimum Concentration (Cmin) of Rociletinib and Metabolites</title>
          <description>Blood sampling for PK analyses of both rociletinib and MPDL3280A will be conducted in all patients treated with rociletinib and MPDL3280A. Cmin will be estimated for rociletinib, using non-compartmental models. Comparisons across dose levels will be made to assess proportionality.</description>
          <population>Due to the small number of patients enrolled and small number of PK samples collected as a result of early termination of the study, these analyses were not conducted.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve (AUC) of Rociletinib and Rociletinib Metabolites</title>
        <description>Blood sampling for PK analyses of both rociletinib and MPDL3280A will be conducted in all patients treated with rociletinib and MPDL3280A. AUC0 24 will be estimated for rociletinib, using non-compartmental models. Comparisons across dose levels will be made to assess proportionality.</description>
        <time_frame>Treatment Day 1 and Day 8</time_frame>
        <population>Due to the small number of patients enrolled and small number of PK sample collected as a result of early termination of the study, these analyses were not conducted.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Arm Rociletinib and MPDL3280A in Combination</title>
            <description>Rociletinib (CO-1686), a novel, potent, covalent (irreversible) small molecule, tyrosine kinase inhibitor (TKI) administered orally (PO) to patients with EGFRm NSCLC in combination with MPDL3280A, a human IgG1 monoclonal antibody administered intravenously (IV).</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) of Rociletinib and Rociletinib Metabolites</title>
          <description>Blood sampling for PK analyses of both rociletinib and MPDL3280A will be conducted in all patients treated with rociletinib and MPDL3280A. AUC0 24 will be estimated for rociletinib, using non-compartmental models. Comparisons across dose levels will be made to assess proportionality.</description>
          <population>Due to the small number of patients enrolled and small number of PK sample collected as a result of early termination of the study, these analyses were not conducted.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Concentration (Cmax) of MPDL3280A</title>
        <description>Blood sampling for PK analyses of both rociletinib and MPDL3280A will be conducted in all patients treated with rociletinib and MPDL3280A. Cmax, for MPDL3280A will be assessed using non-compartmental models. Comparisons across dose levels will be made to assess proportionality.</description>
        <time_frame>Cycle 1 Day 1</time_frame>
        <population>Due to the small number of patients enrolled and small number of PK samples collected as a result of early termination of the study, these analyses were not conducted.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Arm Rociletinib and MPDL3280A in Combination</title>
            <description>Rociletinib (CO-1686), a novel, potent, covalent (irreversible) small molecule, tyrosine kinase inhibitor (TKI) administered orally (PO) to patients with EGFRm NSCLC in combination with MPDL3280A, a human IgG1 monoclonal antibody administered intravenously (IV).</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Concentration (Cmax) of MPDL3280A</title>
          <description>Blood sampling for PK analyses of both rociletinib and MPDL3280A will be conducted in all patients treated with rociletinib and MPDL3280A. Cmax, for MPDL3280A will be assessed using non-compartmental models. Comparisons across dose levels will be made to assess proportionality.</description>
          <population>Due to the small number of patients enrolled and small number of PK samples collected as a result of early termination of the study, these analyses were not conducted.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Minimum Concentration (Cmin) of MPDL3280A</title>
        <description>Blood sampling for PK analyses of both rociletinib and MPDL3280A will be conducted in all patients treated with rociletinib and MPDL3280A. Cmin for MPDL3280A will be assessed using non-compartmental models. Comparisons across dose levels will be made to assess proportionality.</description>
        <time_frame>Approximately every 6 weeks up to 24 months</time_frame>
        <population>Due to the small number of patients enrolled and small number of PK samples collected as a result of early termination of the study, these analyses were not conducted.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Arm Rociletinib and MPDL3280A in Combination</title>
            <description>Rociletinib (CO-1686), a novel, potent, covalent (irreversible) small molecule, tyrosine kinase inhibitor (TKI) administered orally (PO) to patients with EGFRm NSCLC in combination with MPDL3280A, a human IgG1 monoclonal antibody administered intravenously (IV).</description>
          </group>
        </group_list>
        <measure>
          <title>Minimum Concentration (Cmin) of MPDL3280A</title>
          <description>Blood sampling for PK analyses of both rociletinib and MPDL3280A will be conducted in all patients treated with rociletinib and MPDL3280A. Cmin for MPDL3280A will be assessed using non-compartmental models. Comparisons across dose levels will be made to assess proportionality.</description>
          <population>Due to the small number of patients enrolled and small number of PK samples collected as a result of early termination of the study, these analyses were not conducted.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Objective Response Rate Per RECIST v1.1 in Phase 2</title>
        <description>To determine the efficacy of the combination of rociletinib and MPDL3280A based on overall response rate per RECIST v1.1 in the following groups of patients:
Group A: Patients with EGFRm advanced or metastatic NSCLC who have not previously received an EGFR TKI or chemotherapy.
Group B: Patients with EGFRm advanced or metastatic NSCLC who have progressed on a prior EGFR TKI.</description>
        <time_frame>Approximately every 6-9 weeks</time_frame>
        <population>Given the early termination of the study and that no patients were enrolled in Phase 2 of the study, no conclusions can be drawn.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Arm Rociletinib and MPDL3280A in Combination</title>
            <description>Rociletinib (CO-1686), a novel, potent, covalent (irreversible) small molecule, tyrosine kinase inhibitor (TKI) administered orally (PO) to patients with EGFRm NSCLC in combination with MPDL3280A, a human IgG1 monoclonal antibody administered intravenously (IV).</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate Per RECIST v1.1 in Phase 2</title>
          <description>To determine the efficacy of the combination of rociletinib and MPDL3280A based on overall response rate per RECIST v1.1 in the following groups of patients:
Group A: Patients with EGFRm advanced or metastatic NSCLC who have not previously received an EGFR TKI or chemotherapy.
Group B: Patients with EGFRm advanced or metastatic NSCLC who have progressed on a prior EGFR TKI.</description>
          <population>Given the early termination of the study and that no patients were enrolled in Phase 2 of the study, no conclusions can be drawn.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate Per Modified RECIST v1.1, Incorporating Immune-related Criteria, in Phase 2</title>
        <description>Conventional response criteria may not be adequate to characterize the antitumor activity of immunotherapeutic agents like MPDL3280A, which can produce delayed responses that may be preceded by initial apparent radiological progression, including the appearance of new lesions. Therefore, modified response criteria have been developed that account for the possible appearance of new lesions and allow radiological progression to be confirmed at a subsequent assessment. In this protocol, patients will be permitted to continue study treatment even after modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria for progressive disease are met if the benefit-risk ratio is judged to be favorable.
These modified criteria are derived from RECIST version 1.1 (v1.1) conventions and immune related response criteria (irRC).</description>
        <time_frame>Approximately every 6-9 weeks, up to 24 months</time_frame>
        <population>Given the early termination of the study and that no patients were enrolled in Phase 2 of the study, no conclusions can be drawn.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Arm Rociletinib and MPDL3280A in Combination</title>
            <description>Rociletinib (CO-1686), a novel, potent, covalent (irreversible) small molecule, tyrosine kinase inhibitor (TKI) administered orally (PO) to patients with EGFRm NSCLC in combination with MPDL3280A, a human IgG1 monoclonal antibody administered intravenously (IV).</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate Per Modified RECIST v1.1, Incorporating Immune-related Criteria, in Phase 2</title>
          <description>Conventional response criteria may not be adequate to characterize the antitumor activity of immunotherapeutic agents like MPDL3280A, which can produce delayed responses that may be preceded by initial apparent radiological progression, including the appearance of new lesions. Therefore, modified response criteria have been developed that account for the possible appearance of new lesions and allow radiological progression to be confirmed at a subsequent assessment. In this protocol, patients will be permitted to continue study treatment even after modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria for progressive disease are met if the benefit-risk ratio is judged to be favorable.
These modified criteria are derived from RECIST version 1.1 (v1.1) conventions and immune related response criteria (irRC).</description>
          <population>Given the early termination of the study and that no patients were enrolled in Phase 2 of the study, no conclusions can be drawn.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response Per RECIST v1.1 and Modified RECIST v1.1, Incorporating Immune-related Criteria, in Phase 2</title>
        <description>Conventional response criteria may not be adequate to characterize the antitumor activity of immunotherapeutic agents like MPDL3280A, which can produce delayed responses that may be preceded by initial apparent radiological progression, including the appearance of new lesions. Therefore, modified response criteria have been developed that account for the possible appearance of new lesions and allow radiological progression to be confirmed at a subsequent assessment. In this protocol, patients will be permitted to continue study treatment even after modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria for progressive disease are met if the benefit-risk ratio is judged to be favorable.
These modified criteria are derived from RECIST version 1.1 (v1.1) conventions and immune related response criteria (irRC).</description>
        <time_frame>Approximately every 6-9 weeks, up to 24 months</time_frame>
        <population>Given the early termination of the study and that no patients were enrolled in Phase 2 of the study, no conclusions can be drawn.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Arm Rociletinib and MPDL3280A in Combination</title>
            <description>Rociletinib (CO-1686), a novel, potent, covalent (irreversible) small molecule, tyrosine kinase inhibitor (TKI) administered orally (PO) to patients with EGFRm NSCLC in combination with MPDL3280A, a human IgG1 monoclonal antibody administered intravenously (IV).</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response Per RECIST v1.1 and Modified RECIST v1.1, Incorporating Immune-related Criteria, in Phase 2</title>
          <description>Conventional response criteria may not be adequate to characterize the antitumor activity of immunotherapeutic agents like MPDL3280A, which can produce delayed responses that may be preceded by initial apparent radiological progression, including the appearance of new lesions. Therefore, modified response criteria have been developed that account for the possible appearance of new lesions and allow radiological progression to be confirmed at a subsequent assessment. In this protocol, patients will be permitted to continue study treatment even after modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria for progressive disease are met if the benefit-risk ratio is judged to be favorable.
These modified criteria are derived from RECIST version 1.1 (v1.1) conventions and immune related response criteria (irRC).</description>
          <population>Given the early termination of the study and that no patients were enrolled in Phase 2 of the study, no conclusions can be drawn.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival Per RECIST v1.1 and Modified RECIST v1.1, Incorporating Immune-related Criteria, in Phase 2</title>
        <description>Conventional response criteria may not be adequate to characterize the antitumor activity of immunotherapeutic agents like MPDL3280A, which can produce delayed responses that may be preceded by initial apparent radiological progression, including the appearance of new lesions. Therefore, modified response criteria have been developed that account for the possible appearance of new lesions and allow radiological progression to be confirmed at a subsequent assessment. In this protocol, patients will be permitted to continue study treatment even after modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria for progressive disease are met if the benefit-risk ratio is judged to be favorable.
These modified criteria are derived from RECIST version 1.1 (v1.1) conventions and immune related response criteria (irRC).</description>
        <time_frame>Approximately every 6-9 weeks, up to 24 months</time_frame>
        <population>Given the early termination of the study and that no patients were enrolled in Phase 2 of the study, no conclusions can be drawn.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Arm Rociletinib and MPDL3280A in Combination</title>
            <description>Rociletinib (CO-1686), a novel, potent, covalent (irreversible) small molecule, tyrosine kinase inhibitor (TKI) administered orally (PO) to patients with EGFRm NSCLC in combination with MPDL3280A, a human IgG1 monoclonal antibody administered intravenously (IV).</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival Per RECIST v1.1 and Modified RECIST v1.1, Incorporating Immune-related Criteria, in Phase 2</title>
          <description>Conventional response criteria may not be adequate to characterize the antitumor activity of immunotherapeutic agents like MPDL3280A, which can produce delayed responses that may be preceded by initial apparent radiological progression, including the appearance of new lesions. Therefore, modified response criteria have been developed that account for the possible appearance of new lesions and allow radiological progression to be confirmed at a subsequent assessment. In this protocol, patients will be permitted to continue study treatment even after modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria for progressive disease are met if the benefit-risk ratio is judged to be favorable.
These modified criteria are derived from RECIST version 1.1 (v1.1) conventions and immune related response criteria (irRC).</description>
          <population>Given the early termination of the study and that no patients were enrolled in Phase 2 of the study, no conclusions can be drawn.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Alive at Study Termination</title>
        <description>Patients who received the combination of rociletinib and MPDL3280A alive at the termination of this study.</description>
        <time_frame>Up to approximately 18.5 months</time_frame>
        <population>Count of the number of enrolled patients alive at study termination.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Arm Rociletinib and MPDL3280A in Combination</title>
            <description>Rociletinib (CO-1686), a novel, potent, covalent (irreversible) small molecule, tyrosine kinase inhibitor (TKI) administered orally (PO) to patients with EGFRm NSCLC in combination with MPDL3280A, a human IgG1 monoclonal antibody administered intravenously (IV).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Alive at Study Termination</title>
          <description>Patients who received the combination of rociletinib and MPDL3280A alive at the termination of this study.</description>
          <population>Count of the number of enrolled patients alive at study termination.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Longitudinal Changes in Blood Based Biomarkers (eg, Mutations in EGFR) in ctDNA</title>
        <description>Tumor tissue, plasma, and blood specimens will be used for pharmacodynamic assessment of rociletinib and/or MPDL3280A activity, to evaluate the concordance of mutant EGFR detection between tissue and plasma, and to explore biomarkers that may be predictive of response or resistance to rociletinib and/or MPDL3280A. Biomarkers and changes in biomarker status will be investigated for associations with rociletinib and/or MPDL3280A exposure, safety, and clinical activity. Given the limited sample size, no formal statistical analysis is planned.</description>
        <time_frame>Blood samples will be collected from each patient approximately every 3 weeks, up to 24 months</time_frame>
        <population>Due to the small number of patients enrolled and small number of samples collected as a result of early termination of the study, these analyses were not conducted.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Arm Rociletinib and MPDL3280A in Combination</title>
            <description>Rociletinib (CO-1686), a novel, potent, covalent (irreversible) small molecule, tyrosine kinase inhibitor (TKI) administered orally (PO) to patients with EGFRm NSCLC in combination with MPDL3280A, a human IgG1 monoclonal antibody administered intravenously (IV).</description>
          </group>
        </group_list>
        <measure>
          <title>Longitudinal Changes in Blood Based Biomarkers (eg, Mutations in EGFR) in ctDNA</title>
          <description>Tumor tissue, plasma, and blood specimens will be used for pharmacodynamic assessment of rociletinib and/or MPDL3280A activity, to evaluate the concordance of mutant EGFR detection between tissue and plasma, and to explore biomarkers that may be predictive of response or resistance to rociletinib and/or MPDL3280A. Biomarkers and changes in biomarker status will be investigated for associations with rociletinib and/or MPDL3280A exposure, safety, and clinical activity. Given the limited sample size, no formal statistical analysis is planned.</description>
          <population>Due to the small number of patients enrolled and small number of samples collected as a result of early termination of the study, these analyses were not conducted.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were reported from the date of first dose of study drug and until 28 days after the last dose of study drug.</time_frame>
      <desc>One patient withdrew consent during the washout period having only received rociletinib. This patient did not receive MPDL3280A.</desc>
      <group_list>
        <group group_id="E1">
          <title>Single Arm Rociletinib and MPDL3280A in Combination</title>
          <description>Rociletinib (CO-1686), a novel, potent, covalent (irreversible) small molecule, tyrosine kinase inhibitor (TKI) administered orally (PO) to patients with EGFRm NSCLC in combination with MPDL3280A, a human IgG1 monoclonal antibody administered intravenously (IV).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Eustachian tube dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Bilateral hearing loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataracts</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Stomach Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Epigastric pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Swelling finger</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Herpes virus reactivation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Increased Blood Sugar</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Stomach Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Prolonged QTc interval</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Intermittent epigastric discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Elevated aspartate aminotransferase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Elevated alanine aminotransferase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Elevated blood alkaline phosphatase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Cramps</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Firm raised lesion, dorsum of left foot</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study was terminated early which lead to small number of subjects analyzed. The study did not reach the target number of participants needed to achieve target power and statistically reliable results.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Elizabeth Bradley</name_or_title>
      <organization>Clovis Oncology, Inc.</organization>
      <phone>1-415-409-5495</phone>
      <email>ebradley@clovisoncology.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

